Sign up USA
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: Two top decliners are the subject of negative coverage from a popular investing site

Farmland Partners and Simulations Plus both fell double-digits following the reports
Small-Cap Snapshot: Two top decliners are the subject of negative coverage from a popular investing site
Simulations Plus also released lower-than-expected fiscal third-quarter results

The two top small-cap decliners of the day were on the receiving end of negative coverage from popular investing site Seeking Alpha Wednesday. Both articles were written by authors using pseudonyms and a disclaimer was added saying that the stories may not be updated.

Farmland Partners Inc (NYSE:FPI) shares sank after a Seeking Alpha article claimed that the company was artificially increasing revenues. The company has been accused of making loans to members of its management team who then circle the cash back as rent. the story alleges that its 2017 earnings may be “made-up.” Shares of the farm real estate company fell more than 20% to US$6.91 in Wednesday morning trading.

Simulations Plus Inc (NASDAQ:SLP) released its fiscal third-quarter results, reporting earnings of US$0.13 per share on revenue of US$8.6mln. While its revenue surpassed analyst estimates, shares slumped after a Seeking Alpha article alleged that the software company would soon see a decline of up to 70%. The article claims that the stock price is not justified by its fundamentals. The company’s former CEO, Walt Woltosz, the engineer who developed the technology that allowed famed physicist Stephen Hawking to communicate, recently retired. Shares of the California-based company sunk more than 20% to US$18.15.

Neither company has issued a response to the Seeking Alpha articles as of the time this story was published.

AngioDynamics Inc (NASDAQ:ANGO) shares took a hit after releasing disappointing fiscal fourth-quarter earnings. The medical device company posted earnings of US$0.20 per share on revenue of US$88.3mln. Wall Street was expecting earnings of US$0.21 per share on revenue of US$89mln. The company sells surgical and diagnostic devices for the treatment of heart disease. Shares of the New York-based company were down more than 12% to US$20.

READ: AngioDynamics’ stock tumbles after fiscal 4Q earnings miss on lukewarm revenue

Asterias Biotherapeutics Inc (NYSE:AST) shares soared after a safety review committee recommended that the study of its cancer immunotherapy product continues. Its drug AST-VAC2 is an immunotherapy that targets tumor cells. The clinical trial will examine the effects of the drug on non-small cell lung cancer. Shares of the California-based biotech were up nearly 15% to US$1.77.

Achieve Life Sciences Inc (NASDAQ:ACHV) shares are up following a meeting with US Food and Drug Administration. The company discussed the next steps for bringing its smoking cessation drug cystine to the US market. Its Phase 2b trial will see if the number of cigarettes smoked while undergoing treatment is reduced. Shares of the Washington-based biotech jumped more than 30% to US$4.81.

View full SLP profile View Profile

Simulations Plus Timeline

Related Articles

Apps on a smartphone
July 06 2018
“As of today, appScatter tracks 1.2bln app URLs, from 10.7mln apps and 2.9mln publishers,” chairman Clive Carver told shareholders at the AGM in June
Young girl with laptop
May 17 2018
After mulling for almost a year whether to "draw stumps" and sell out, MMX decided a better course of action was to be the party doing the consolidating
1534442111_IoT.jpg
August 16 2018
In March, it formed a joint venture with New Hope Data Technology Co Ltd, which is affiliated to conglomerate New Hope Group

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use